Alx Oncology Holdings (ALXO) EBITDA Margin (2019 - 2020)
Alx Oncology Holdings (ALXO) posted EBITDA Margin of 2046.87% for Q2 2020, down 155.76% sequentially from 800.31% in Q1 2020, and down 172339.0% YoY from N/an in Q3 2019.
Alx Oncology Holdings (ALXO) EBITDA Margin (2019 - 2020) Analysis & Trends
Alx Oncology Holdings has reported EBITDA Margin for 2 years, with the latest figure at 2046.87% in Q2 2020.
- Quarterly EBITDA Margin fell 172339.0% year-over-year to 2046.87% in Q2 2020, while the trailing twelve-month figure through Mar 2021 was 9986.53% (down 952946.0% YoY) and the FY2020 annual result came in at 3693.99%, down 329401.0% from the prior year.
- EBITDA Margin declined to 2046.87% in Q2 2020 per ALXO's latest filing, from 800.31% in the prior quarter.
- Over five years, EBITDA Margin peaked at 241.56% in Q3 2019 and troughed at 2046.87% in Q2 2020.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 37.40% |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 30.15% |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 31.68% |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 19.06% |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -77,569,866.34% |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 19.75% |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 17.93% |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -0.36% |
| 10 | Alx Oncology Holdings | 270.90 Mn | 270.90 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2020 | -2,046.87% |
| Mar 31, 2020 | -800.31% |
| Dec 31, 2019 | -637.51% |
| Sep 30, 2019 | -241.56% |
| Jun 30, 2019 | -323.47% |